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Hsp90Quality control processes regulate the proteome by determining whether a protein is to be folded or
degraded. Hsp90 is a hub in the network of molecular chaperones that maintain this process because it
promotes both folding and degradation, in addition to regulating expression of other quality control
components. The signiﬁcance of Hsp90's role in quality control is enhanced by the function of its clients,
which include protein kinases and transcription factors, in cellular signaling. The inhibition of Hsp90 with
small molecules results in the rapid degradation of such clients via the ubiquitin/proteasome pathway, and
also in the induction of the Hsp70 molecular chaperone. These two events result in markedly different
outcomes depending on cell type. For tumor cells there is a profound loss of signaling in growth promoting
pathways. By contrast, increased amounts of Hsp70 in neuronal cells ameliorate the toxicity that is associated
with the formation of aggregates observed in neurodegenerative conditions. In this review we discuss the
mechanisms underlying these differential effects of Hsp90 inhibition on the quality control of distinct client
proteins. This article is part of a Special Issue entitled: Heat Shock Protein 90 (HSP90).hock Protein 90 (HSP90).
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Quality control processes maintain proteome integrity by ensuring
that newly made proteins fold rather than aggregate, and by
promoting the degradation of misfolded proteins. Three cellular
machineries control these processes: molecular chaperones interact-
ing with nascent and unfolded/misfolded proteins to determine their
fate, the ubiquitin/proteasome system for the degradation of
misfolded proteins, and the autophagic system for the removal of
aggregates and other misfolded proteins [1,2]. Fig. 1 shows in outline
the relationship between molecular chaperones and components of
the ubiquitin proteasome pathway in relation to the quality control
process and the three fates for a protein: folding, degradation or
aggregation.
Quality control pathways exist because proteins fold in an
unfavorable cellular environment for this process due to molecular
crowding and relatively high temperatures [3]. These two conditions,
when combined, favor aggregation over folding. Molecular chaper-
ones evolved to shift the equilibrium towards folding by preventing
aggregation. This is achieved via weak interactions between the
molecular chaperones and the exposed hydrophobic groups of
unfolded or misfolded proteins. Under normal cellular conditions
the expression level of molecular chaperones is matched to the overall
level of protein synthesis so that folding is the expected fate for newlymade proteins. Under stressful conditions, mature proteins unfold and
exceed the capacity of chaperone networks to prevent aggregation.
This type of proteotoxic stress induces feedback regulation which
results in increased expression of genes encoding molecular chaper-
ones, due to the de-repression of the heat shock transcription factor,
Hsf1. Importantly, Hsp90 plays a role in Hsf1 repression via direct
interaction. Under stress conditions, or inhibition with small
molecules, Hsp90 dissociates resulting in Hsf1 activation [4]. In
addition to acutely stressful events, aging is associated with the
accumulation of aggregates containing oxidatively damaged proteins.
It seems clear, however, that aggregation represents an end state that
the cell attempts to avoid by directing damaged or misfolded proteins
to the ubiquitin/proteasome system. It is only when this system
becomes overwhelmed that aggregation ensues.
The role of the Hsp90 molecular chaperone in quality control
processes is essential and its deregulation can affect several diseases
from cystic ﬁbrosis and tumor progression to neurodegenerative
conditions [5–7]. All of these facets of Hsp90 function are linked
directly to the clients it is helping to fold, which includemany proteins
important for cellular signaling, including transcription factors and
protein kinases. In this review we describe the mechanisms by which
Hsp90 controls the fate of its clients in the context of the quality
control systems of the cell.
While early studies focused on client protein folding, Hsp90's
integration into a larger quality control system was not appreciated
until the benzoquinoid ansamycin, geldanamycin, was shown to be a
speciﬁc inhibitor of the chaperone [8]. Subsequent studies revealed
that client protein kinases and transcription factors were rapidly
destroyed via the ubiquitin/proteasome pathway. This set the stage
Fig. 1. Outline of the cytosolic quality control process. Three major outcomes for a newly synthesized protein are shown: folding, aggregation and degradation via the
ubiquitin/proteasome system. Proteins shown in blue are co-chaperones that can promote client protein folding. Sse1, shown in purple, promotes degradation of Hsp90 clients.
Select ubiquitin ligases known to promote the degradation of Hsp90 clients are shown in red. Individual proteins are discussed throughout the review. The process of autophagy,
which clears protein aggregates is not depicted.
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more than 13 small molecules currently in clinical trials as
chemotherapeutics [9]. The consequence of Hsp90 inhibition to the
emergence of a rare phenotype was later established with the
demonstration that geldanamycin treatment led to the emergence
of hidden morphological characteristics in Drosophila melanogaster
and Arabidopsis, as well as differential responses to stress in yeast [10–
13]. These ﬁndings led to the hypothesis that Hsp90 acts as a capacitor
by helping to fold polymorphic variants of the same protein even
though their folding efﬁciencies vary. This was observed with v-Src,
an unstable protein kinase, which has a greater requirement for
Hsp90 than its cellular counterpart c-Src [14]. Similarly, mutant forms
of p53 and B-Raf protein kinase have stronger interactions with
molecular chaperones than do their wild type counterparts [15–17].
Hsp90, therefore, sits at the nexus of folding and degradation
pathways, with small molecule inhibitors pushing the equilibrium
strongly towards the destructive fate.
1.1. Small molecule Hsp90 inhibitors and client protein degradation: role
of molecular chaperones in fate determination
It iswell established that Hsp90 sits at the distal end of the pathway
of chaperone interactions for newly made transcription factors and
protein kinases [18]. For example, newly made nuclear receptors such
as the glucocorticoid receptor and the progesterone receptor interactwith Hsp70 and Hsp40 chaperones prior to recruitment to Hsp90 by
the actions of Hop/Sti1—the Hsp organizing protein [19]. Likewise,
protein kinases are recruited to Hsp90 via the actions of Sti1 and the
kinase-speciﬁc chaperone Cdc37 [20–22]. The entry of Hsp90 into this
system is associated with the folding of the client itself. Although the
mechanism by which client protein folding is coordinated with
Hsp90's reaction cycle is largely unclear, there appears to be a closing
in of the chaperone around its clients when they interact [23]. What is
clear, however, is that many small molecule inhibitors act by means of
competitive inhibition of Hsp90's ATPase, which occurs in the N-
domain of the chaperone. The speciﬁcity of such inhibitors is related to
the unusual bent conformation of ATP as it resides in the N-domain
[24].
The inhibition of Hsp90 with N-terminal inhibitors results in rapid
degradationvia theubiquitin/proteasomepathway formany, butnot all,
clients. This outcome is observed for many protein kinase clients
including Akt and Cdk4 as shown in Fig. 2. Note also how Hsp70 is
induced in a reciprocal mannerwith protein kinase degradation (Fig. 2)
as a result of Hsf1 de-repression. Protein kinases susceptible to loss of
Hsp90 function include newly made protein kinases as well as mature
clients that enter into multiple rounds of interaction [25,26]. The
mechanisms by which inhibitors promote degradation are not entirely
clear. It seems likely that N-terminal inhibitors do not reprogramHsp90
to actively promote degradation, but rather, that degradation is a
consequence of blocking the folding pathway. N-terminal Hsp90
Fig. 2. Effect of Hsp90 inhibition on protein kinase clients and induction of Hsp70. A
Western blot analysis is shown based on a dose-dependent study of 17-AAG in mouse
Ba/F3 cells over a 24 h period. Proteins indicated include the Hsp70 molecular
chaperone as well as Akt and Cdk4 protein kinase clients of Hsp90.
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plexes. For protein kinases, there is an increase in Hsp70 binding to the
client coupled with a reduction in Hsp90 binding. Such complexes are
likely to contain Sti1/Hop, but not Cdc37 [27]. These ﬁndings correlate
with the role of Hsp70 in degradation processes [28]. As described in
more detail below, this may have a lot to do with Hsp70's ability to
coordinate with different ubiquitin ligases, including CHIP and Ubr1
[29–31].
Several molecular chaperones and co-chaperones other than Hsp70
function in both folding and degradation processes. Sse1, the Hsp110
chaperone that acts as a nucleotide exchange factor for Hsp70 [32] is
required for the degradation of client protein kinases in cells treated
with geldanamycin [33]. This action requires direct interaction between
Sse1 and Hsp70 and occurs before the protein is ubiquitylated. By
contrast, loss of function of the Hsp40 co-chaperone, Ydj1, leads to a
rapid degradation of protein kinases, suggesting that it has a protective
role for newly made Hsp90 clients [34]. However, several other studies
showed that Hsp40 co-chaperones are required for the degradation of
unstable or mutant proteins, suggesting that this class of co-chaperone
may have diverse functions in the quality control process [35–39]. Ydj1
also functions as an Hsp70 co-chaperone, and stimulates Hsp70's
ATPase, thereby stabilizing Hsp70:client complexes [40]. The distinct
roles of Ydj1 and Sse1 as Hsp70 co-chaperones suggests a model in
which the stable association of a client with Hsp70 is protective against
degradation for newlymade proteins. By contrast, complex dissociation
is required for degradationwhen folding pathways are inhibited such as
with geldanamycin.
The protective role of Ydj1 for newly made Hsp90 client protein
kinases is similar to the actions of Cdc37, the kinase speciﬁc chaperone.
Cdc37 is well characterized for its ability to interact directly with
protein kinases and also with Hsp90 [41]. This action serves to both
protect the newly made protein kinase and also promote stable
interaction with Hsp90 [22,42,43]. Indeed, Cdc37 has a wide-ranging
role in the biogenesis of the protein kinome and serves to protect an
estimated 75% of all protein kinases in yeast against rapid degradation
either during or shortly after translation via the ubiquitin/proteasome
pathway [42]. Importantly, the actions of Cdc37 and Ydj1 do not
overlap since they cannot substitute for each other in the protection of
newly made protein kinases [34]. This speciﬁcity suggests that they
each interact with a unique region of the newly made kinase client
prior to transfer to Hsp70 (via Ydj1) and Hsp90 (via Cdc37). These
transfer reactions lead to further stabilization and folding unless the
system is challenged by an Hsp90 inhibitor. In this case, the chaperone
apparatus is reprogrammed away from its protective function and the
pro-degradative roles of Hsp70 and Hsp110 are enabled.1.2. Hsp90 can promote degradation
The sense that Hsp90 inhibitors promote degradation by loss of
function can be misleading. There are several reports, for example,showing that Hsp90 is required for degradation of membrane proteins
in the endoplasmic reticulum. These include cytochrome p450 2E1,
mutant CFTRΔF508 and Apolipoprotein B. In each of these cases,
geldanamycin was found to inhibit degradation in cell free systems
when the substrate was added to cytosolic extracts in the form of
microsomes. [44–46]. The degradation of a mutant form of the insulin
receptor was also reduced upon injection of Hsp90 antibodies into
cells [47]. By contrast, studies in yeast showed that a cytosolic protein,
albeit one that was heterologously expressed can be degraded in an
Hsp90-dependent manner. In this case, using VHL as a model protein,
Hsp90was shown to be required for degradation but not for folding in
vivo [39].
The example of CFTRΔF508 is intriguing since this mutant form is
stabilized upon Hsp90 inhibition in vitro, while the wild type
counterpart is destabilized in cells treated with geldanamycin [48].
This could reﬂect differences in experimental approach, but a more
compelling possibility is that a distinction in the folding potential of
the client may be important for determining the relative contribution
of Hsp90 to the quality control process. Evidence for this comes from
mass spectrometric analysis of wild type and ΔF508 versions of CFTR.
Strikingly, the latter is complexed with Hsp90 co-chaperones not
observed to associate with wild type CFTR, including Hop/Sti1 [7],
which was also required for degradation of VHL [39]. Furthermore,
modulation of Aha1, which catalyzes Hsp90's ATPase, results in
profound changes to the fate of CFTRΔF508. Decreasing Aha1 levels
results in the stabilization of CFTRΔF508 and a shift towards the
folded form that translocates to the plasma membrane, while Aha1
overexpression leads to increased CFTRΔF508 turnover [7]. These
ﬁndings suggest that the chaperone apparatus can be reprogrammed
depending on the folding status of the client, and that clients whose
folding potential is low eventually interact with a chaperone cohort
that promotes degradation. However, a certain amount of caution is
warranted in extrapolating results from the study of one client. While
downregulation of Aha1 promotes the stabilization of CFTRΔF508, it
also sensitizes cells to Hsp90 inhibitors, which could reﬂect a relative
destabilization of other clients [49].
In addition, recent studies suggest that some membrane proteins
including CFTR can be removed from the plasma membrane in a
chaperone-dependent manner for degradation via the lysosome
rather than the proteasome [50–52].
1.3. Role of ubiquitin ligases in the degradation of Hsp90 client proteins
Ubiquitylation is important for the targeting of misfolded protein
substrates to the proteasome. Ubiquitin is ﬁrst activated via a
thioester linkage catalyzed by an E1 enzyme prior to transfer to the
E2 ubiquitin conjugating enzymes. The ﬁnal transfer of ubiquitin to
the substrate requires the action of the E3 or ubiquitin ligase, which
acts in association with the E2s. Ubiquitin chains, that grow via lysine
48 linkage conventionally, become targets for receptors on the 19S
regulatory particle of the proteasome [53,54]. Ubiquitin is removed
prior to substrate transfer to the 20S catalytic core of the protease. The
family of ubiquitin ligases is large and diverse and several are known
to speciﬁcally target misfolded proteins to the proteasome and to
work with molecular chaperones in this process [55,56].
1.3.1. CHIP
The best-characterized ubiquitin ligase that functions in cytosolic
quality control is CHIP (Carboxyl terminus of Hsc70-Interacting
Protein). CHIP is a 35 kDa protein containing three tandem tetratrico-
peptide (TPR) motifs in its NH2-terminal region that interact directly
with Hsp70 and Hsp90 [57–59]. At its C-terminus is the U-box [60] that
is a modiﬁed version of the RING ﬁnger domain that is responsible for
the intrinsic E3 ubiquitin ligase activity [61]. The E2s that function with
CHIP belong to the mammalian UBCH5 family that is closely related to
yeast Ubc4 and Ubc5 [60,61]. CHIP has been characterized to help in the
686 M.A. Theodoraki, A.J. Caplan / Biochimica et Biophysica Acta 1823 (2012) 683–688disposal of a great many Hsp70 client proteins, and our discussion here
will focus on those that also require Hsp90.
One of the best-studied clients of Hsp90 is the glucocorticoid
receptor (GR [62]). The assembly of the GR in vitro needs a minimum
of 5 components; Hsp90, Hsp70, Hsp40, HOP and p23. In the absence
of a ligand, Hsp90 binds to GR and maintains the receptor in a
hormone binding competent conformation. The treatment of cells
with geldanamycin results in loss of p23 binding to GR, disruption of
the hormone-binding activity, and increased proteasomal degrada-
tion [63]. The addition of CHIP leads to a similar remodeling of the
Hsp90 complex, with a reduced association of HOP and the release of
p23 [29]. Most importantly, incubation of CHIPwith in vitro translated
GR led to the formation of a high molecular mass, ubiquitylated
species of the receptor. The Hsp70 co-chaperone BAG-1M, which is
also known to inhibit GR assembly and hormone binding [64] had no
effect on GR ubiquitylation, suggesting that the ubiquitylation of GR is
not simply a result of the remodeling of the Hsp90 complex.
Similar results on the effect of CHIP on GR have been reported in
studies of the estrogen receptor (ERα). The ligand free receptor is
short lived, but in the presence of a ligand the turnover of ERα can be
increased or decreased. Increased turnover is promoted by the
binding of the cognate ligand 17β-estradiol, ATP depletion, or by
Hsp90 inhibition by geldanamycin or radicicol. Overexpression of
CHIP was also found to increase the ubiquitylation and subsequent
degradation of ERα through the proteasomal pathway, while CHIP
depletion by small interfering RNA resulted in increased levels of ERα
and increased reporter gene transactivation. Upon geldanamycin
treatment the interaction between CHIP and ERα was enhanced and
the ERα degradation was further increased [65]. In the case of the
androgen receptor (AR), overexpression of CHIP reduces the levels of
AR in a steady state and induces ubiquitylation. CHIP functions during
translation or shortly after translation with its effects being prior to
ligand binding and Hsp90 binding [66].
CHIP has also been shown to function in the degradation of Hsp90
client protein kinases. ErbB2/Her2 is a member of the ErbB receptor
tyrosine kinase family, which includes the epidermal growth factor
receptor EGFR/ErbB1 and is frequently found over-expressed in
different types of cancer. Her2 homodimerizes or heterodimerizes
with other members of the ErbB family and promotes survival signals.
EGFR homodimers are degraded via the actions of the c-Cbl ubiquitin
ligase, however activated ErbB2 has reduced associationwith c-Cbl. The
stability of both newly synthesized and mature ErbB2 depends on
Hsp90 [67,68]. Upon geldanamycin treatment the Hsp90/ErbB2
complex destabilizes and ErbB2 becomes ubiquitylated and degraded
via the proteasome [69,70]. The sensitivity of ErbB2 to CHIP depends on
the kinase domain of the protein but not on the activity of the kinase.
The effects of CHIP are enhancedwith the addition of geldanamycin and
are independent of c-Cbl E3 ligase activity. Several lines of evidence
converged to demonstrate that CHIP acts via molecular chaperones in
the degradation of ErbB2. For example, mutations in the TPR domain
abrogated CHIP activity on ErbB2 and co-immunoprecipitation exper-
iments demonstrated thatCHIP bindingwithErbB2 is also dependenton
the TPR-domain [69].
Although CHIP can bind to both Hsp70 and Hsp90 via its TPRmotifs,
it is most likely to function in association with Hsp70 to promote client
ubiquitylation. CHIP competes with HOP for Hsp90 binding, suggesting
that a complex that could promote folding and degradation at the same
time does not exist. Based on the in vivo concentrations of Hsp70,
Hsp90, HOP and CHIP, and the dissociation constants of the possible
complexes, Kundrat et al. [71] determined that there should be 10 times
more CHIP–Hsp70 complex compared with free CHIP under non-stress
conditions, suggesting that decisions regarding degradation are taken
while the client is bound to Hsp70. Upon inhibition of Hsp90, the
concentration of Hsp70 in the cell increases 4-fold, much more so than
for other chaperones. Therefore, upon Hsp90 inhibition, folding
complexes containing Hsp70–HOP–Hsp90 complex become unproduc-tive, and since CHIP andHOP are competitive for both chaperones, there
must be a transition of the client fromHsp90:HOP:Hsp70 toHsp70:CHIP
to promote degradation [71].
While CHIP is clearly important for the degradation of the client
types described above, it is not unique in having this function. For
example, there is a reduced degradation of ErbB2 in the CHIP−/−
MEFs treated with geldanamycin, but it is not abolished. This ﬁnding
indicated the presence of other ubiquitin ligases that could substitute
for CHIP. Also, treatment of CHIP−/− MEFs with geldanamycin
promotes the degradation of endogenous GR at the same rate as in
CHIP+/+ cells [72]. Furthermore, the transcription factor HIF-1α is an
Hsp90 client, but its degradation upon geldanamycin treatment is
independent of CHIP [73,74]. As described below, there are now
several examples of ubiquitin ligases that function in addition to CHIP
in the quality control of Hsp90 clients.1.3.2. Ubr1
Ubr1 was shown to act on Hsp90 clients by virtue of its ability to
promote degradation of protein kinases in geldanamycin treated yeast
cells [31]. The ﬁnding was surprising given that Ubr1 was previously
found to function via N-end rule degradation, when the identity of the
N-terminal amino acid determines a protein's half life [75]. However,
Ubr1's action in cytosolic quality control has been observed by other
investigators using mislocalized and unstable proteins [76,77]. For
Hsp90 clients, UBR1 deletion resulted in a reduced degradation of
protein kinase clients. Similarly, Ubr1 was also required for the
degradation of protein kinases in cdc37mutant cells, conﬁrming that
the quality control pathways dependent on Cdc37 and Hsp90 are
similar [31]. Biochemical studies revealed that Ubr1 acts via a direct
interaction with its misfolded protein substrates, because it only
bound with ubiquitylated denatured luciferase and not its native
counterpart. This action, however, must be viewed in the context of
its relative abundance, which is thought to be very low, especially in
comparison with molecular chaperones such as Hsp90, or even
Cdc37 [78,79]. Accordingly, Hsp70 itself stimulated ubiquitylation
by Ubr1 in a puriﬁed system. Together these ﬁndings suggest that
Ubr1 acts in an analogous manner to CHIP.
Yeast Ubr1 has a paralog, Ubr2 that does not function via the N-end
rule. Nevertheless, it does appear to have some function in protein
kinase degradation but the phenotype resulting from its deletion was
mild compared with a ubr1Δ strain. Similarly, deletion of the nuclear
localized San1 also led to a reduced degradation of a protein kinase in
the presence of geldanamycin [31]. Like Ubr1, San1 acts via direct
interaction with its misfolded substrates [80]. At this time it is unclear
to what extent mammalian homologs of Ubr1 have conserved roles in
cytosolic quality control. Yeast San1 functions in nuclear quality
control when expressed inmammalian cells, and proteinswith similar
function to San1 have been identiﬁed [81].1.3.3. Cul5
Cul5 is one of seven members of the cullin family of E3 ubiquitin
ligases. It interacts with both Hsp70 and Hsp90 and appears to play a
direct role in client kinase degradation upon Hsp90 inhibition in
mammalian cells [74]. Inhibition of Hsp90 resulted in an impaired
degradation of ErbB2, when Cul5 was knocked down or when a
dominant negative form of the ubiquitin ligase was overexpressed. In
addition, Cul5 was required for the efﬁcient degradation of Hif1α after
Hsp90 inhibition. Although Cul5 usually functions in association
with adaptor proteins ElonginB and ElonginC, these were not required
for its function in the quality control of Hsp90 clients. This indicates that
ubiquitin ligases engaged in quality control may function both with
speciﬁc clients that depend on protein sequence, and with others
that depend on protein conformation independent of sequence
considerations.
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neurodegeneration
Hsp90 inhibition has direct application as chemotherapy because it
can induce apoptosis and other forms of cell death [82]. In addition, there
is a great interest in Hsp90 inhibitors which cross the blood:brain barrier
that could be used to ameliorate the symptoms of several neurodegen-
erative conditions [6]. The underlying principle of such an action is
embodied in the dual role of Hsp90 inhibitors to promote toxic client
elimination and in Hsp70 induction as a result of Hsf1 derepression.
Several recent studies have demonstrated how increasing Hsp70
levels led to a reduction in the toxicity associatedwith the expression of
proteins that promote neurodegenerative conditions. These include
mutant forms of Huntingtin, which aggregate as a consequence of
expanded polyglutamine tracts [83]. Other examples include α-
synuclein (Parkinson's disease) and Aß (Alzheimer's disease); in each
case, Hsp70 acted to reduce aggregation or ﬁbril formation [84,85].
What is intriguing is how Hsp90 inhibitors help to reduce toxicity of
such proteins by stimulating derepression of Hsf and promoting Hsp70
induction (for review see ref. [6]). This suggests a possible pathway to a
new class of therapeutics that cross the blood brain barrier.
In contrast to the effects of upregulating Hsp70, there are also
examples where Hsp90 inhibition can lead to the degradation of
proteins that are toxic themselves or promote toxicity and neurode-
generation. Examples include the polyglutamine expanded form of
the androgen receptor, which is dependent on Hsp90 for proper
folding [86] and the protein kinase LRKK2 which is associated with
Parkinson's disease [87]. In Alzheimer's disease, hyperphosphoryla-
tion of tau, which leads to its aggregation, can be reduced via Hsp90
inhibitors that affect the stability of Cdk5 activating proteins [88].
1.5. Concluding remarks
Hsp90 inhibition with small molecules alters quality control
processes in ways that promote death of cancer cells and reduced
toxicity in neurons. This seeming paradox shows howHsp90 sits at the
hub of the quality control triage process by controlling folding and
degradation processes while also signaling to Hsf to maintain
chaperone balance. In addition to affecting outcomes in disease
models, Hsp90 also plays an important role in determining phenotype
during development. The central role of Hsp90 in this process appears
to be related to its capacity for folding proteins that are integral to the
signaling capability of the cell, including protein kinases and
transcription factors. As mentioned above, Cdc37, together with
Hsp90, may be responsible for stabilizing and folding of over 75% of
all protein kinases [42], at least in yeast, although the extent of its
inﬂuence over transcription factor folding is still unclear.While the use
of Hsp90 inhibitors in chemotherapy has received mixed results [9],
there is great interest in their use in a broad spectrum of
neurodegenerative conditions. Further exploration of themechanisms
by which Hsp90 inﬂuences proteome quality should lead to a more
deﬁnitive understanding of the place that such inhibitors have in the
treatment of a wide range of late onset diseases.
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